Inhalation Sciences signs SEK 4 million convertible loan facility with Tellus Equity, JEQ Capital, Thalor Capital

• Inhalation Sciences signed a financing agreement for up to SEK 4 million with Tellus Equity, JEQ Capital, Thalor Capital, subject to EGM approval Aug. 18, 2026.
• Facility runs through March 31, 2027. Drawdowns in tranches of at least SEK 500,000.
• Interest set at 1.5% per started calendar month on drawn amounts. A 2.5% cash fee applies on drawn amounts.
• Lenders can convert outstanding amounts into shares from Oct. 1, 2026 at SEK 0.29 per share, subject to corporate actions.
• Company to issue 8,800,000 warrants (TO4) to lenders as consideration, exercisable Sept. 30, 2026 to Sept. 30, 2028 at up to SEK 0.29.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhalation Sciences Sweden AB published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein.